Phase 3 N=151 The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
Type 1 Diabetes Mellitus
Primary: Overall Adverse Event Summary — 67; 55; 23; 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=61 Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
X-Linked Hypophosphatemia
Primary: Radiographic Global Impression of Change (RGI-C) Global Score at Week 40 — 0.77; 1.92 score on a scale — p=< 0.0001
Phase 2 N=92 Pioglitazone for Lung Cancer Chemoprevention
Lung Cancer · Endobronchial Dysplasia
Primary: 6-month Histology Score — 3.07; 3.71 Units on a scale — p=0.53
Early Phase 1 N=18 Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
Active Cocaine Users
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices
Phase 2 N=260 Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Chronic Phase Chronic Myeloid Leukemia
Primary: Percentage of Patients Achieving Major Molecular Response (MMR) After 12 Months of CML Treatment — 12.8; 28.7 Percentage of Patients — p=0.005
N/A N=32 Evaluation of the Baha SoundArc in Pediatric Patients
Hearing Loss, Conductive · Hearing Loss, Mixed · Hearing Loss, Unilateral
Primary: Patient Satisfaction Survey — 65 percentage of satisfied subjects
N/A N=333 Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
Prostate Cancer
Primary: Percentage of Participants Who Had One or More Adverse Events — 4.27 Percentage of Participants
Phase 2 N=40 Dipyridamole for Immune Activation in HIV
HIV Infection
Primary: Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12 — 244500.00; -58250.00 pg/ml — p=0.8220
Phase 3 N=372 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Cutaneous T-Cell Lymphoma
Primary: Progression Free Survival — 55.3; 28.8; 38.3; 15.3 percentage of subjects
Phase 3 N=202 A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Assessment of Systemic Lupus Erythematosus Responder Index (SRI) at Week 52 — 52.5; 44.6 percentage of patient responder — p=0.2631
N/A N=100 Study to Evaluate Safety and Efficacy of Revanesse® Ultra + vs Revanesse® Ultra for Correction of NLF
Nasolabial Fold Correction
Primary: Pain at Injection as Measured by Subject on a 100 mm Visual Analog Scale (VAS) Scale at Time 0 Minutes Post Injection — 26.2; 39.4 VAS
Phase 2 N=40 Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery
Postoperative Ocular Pain After PRK Surgery
Primary: Visual Analog Scale (VAS) Pre-dose Pain Assessment — 34.63; 45.76 score on a scale — p=0.005
Phase 2 N=60 Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Influenza
Primary: Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] — 10; 10; 10; 15 Participants
Phase 3 N=559 A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
Non-small Cell Lung Cancer
Primary: Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 6.4; 4.8 Months — p=<0.0001
Phase 2 N=37 Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Physical Activity
Primary: Change From Baseline of Maximal Oxygen Uptake at Week 12 — 26.9; 30.1; 30.6; 32.4 Milliliters/Kilogram/Minute